4baseCare Secures USD 6 Mn In Series A Funding Led By Yali Capital

4baseCare, an Illumina Accelerator Company specialising in precision oncology through advanced genomics and digital health technologies, has successfully raised USD 6 million in Series A funding. 

In a press statement on Monday, the company informed that the investment round was led by Yali Capital, with additional contributions from other investors. The funds will be used to enhance 4baseCare's product offerings and expand operations across India, as well as in Asia and the Middle East, the statement read.

Mathew Cyriac, Founding General Partner at Yali Capital, remarked, “The genomics landscape in cancer care presents a significant opportunity to impact lives positively while building impactful businesses. We are thrilled by 4baseCare’s progress in improving genomic tests with data from underrepresented populations, which enhances treatment recommendations. The company’s impressive growth and potential make it an exciting venture for us to support.”

Hitesh Goswami, CEO and Co-Founder of 4baseCare, expressed enthusiasm about the funding, stating, “4baseCare was established to fill the critical genomic data gap in cancer care. Our progress with the TARGT Indiegene test and its impact on over 10,000 patients highlights the support from our investors and advisory board. This funding will be pivotal in advancing our mission to provide personalised cancer care to millions.”

4baseCare’s genomic tests have made significant strides in SouthEast Asia, benefiting over 10,000 cancer patients. The company’s Advisory Board includes notable figures such as Francis deSouza, former CEO of Illumina, who brings over 30 years of expertise in genomics and technology.

In the coming months, 4baseCare plans to establish genomics laboratories in the Philippines, Nepal, and Dubai, the company added.